Cancer Diagnosis Project

Cline has recently acquired Liv Diagnostics after working in close collaboration since Liv was founded.  Liv Diagnostics has developed a new unique product to measure the migration behavior of tumor cells, which provides a predictive indicator of metastasis. This information is critical because metastasis causes 90% of all deaths in cancer. Our product CellRACE provides direct and quantified information on the risk of metastasis by analyzing the migration behavior of living cells.

Not only does this method help measure migration behavior but it also generates results within hours, therefore saving time and costs associated with diagnosis. 

The initial development work has been focused on developing a prototype for diagnosing migratory breast cancer cells. We have obtained promising results in measuring the migration capacity of different types of breast cancer cells.

The company has chosen to focus on the diagnosis of tumor cells in breast cancer but estimates that there are good opportunities for the product in other cancer forms. Research and development have been conducted at the AstraZeneca BioVentureHub in Gothenburg, Sweden. Today, Cline is working towards getting a prototype into the clinical phases to be CE marked.

To read more about our Cancer diagnostics project, please click here.